20 May 2013
Keywords: hgs, completes, enrollment, ph, ii, mapatumumab, trial
Article | 01 September 2008
US drug major Human Genome Sciences has completed the enrollment and initial dosing of patients in a randomized Phase II ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
1 September 2008
8 September 2008
17 May 2013
© 2013 thepharmaletter.com